Efavirenz 400 mg versus 600 mg, with TDF-FTC
ENCORE1 Trial
Efavirenz 400 mg versus Efavirenz 600 mg, with TDF-FTC

ENCORE1: Study Design

**Study Design: ENCORE1**

- **Background**: Randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two doses of efavirenz, in combination with co-formulated tenofovir DF and emtricitabine

- **Inclusion Criteria** (n = 636)
  - Antiretroviral-naïve patients
  - Age ≥16
  - HIV RNA ≥1000 copies/mL
  - CD4 count >50 and <500 cells/mm³

- **Treatment Arms**
  - Efavirenz 400 mg QD + TDF-FTC QD
  - Efavirenz 600 mg QD + TDF-FTC QD

**Source**: ENCORE1 Study Group. Lancet. 2014;383:1474-82.
Efavirenz 400 mg versus Efavirenz 600 mg, with TDF-FTC
ENCORE1: Results

Week 48: Virologic Response (Modified Intention-to-Treat)

## Overall Adverse Events

<table>
<thead>
<tr>
<th>Variable</th>
<th>EFV 400 mg n (%)</th>
<th>EFV 600 mg n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of adverse events</td>
<td>1173 (49.8%)</td>
<td>1182 (50.2%)</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of serious adverse events</td>
<td>31 (46.2%)</td>
<td>36 (53.7%)</td>
</tr>
<tr>
<td>Number with serious adverse events</td>
<td>23 (7.17%)</td>
<td>22 (7.12%)</td>
</tr>
<tr>
<td>Number with serious adverse events related to study drug</td>
<td>3 (0.93%)</td>
<td>4 (1.29%)</td>
</tr>
<tr>
<td>Adverse events probably related to study drug</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with adverse events related to study drug</td>
<td>118 (36.8%)</td>
<td>146 (47.2%)</td>
</tr>
<tr>
<td>Patients stopping drug due to drug related adverse event</td>
<td>6 (1.9%)</td>
<td>18 (5.8%)</td>
</tr>
</tbody>
</table>

**Interpretation**: “Our findings suggest that a reduced dose of 400 mg efavirenz is non-inferior to the standard dose of 600 mg, when combined with tenofovir and emtricitabine during 48 weeks in ART-naive adults with HIV-1 infection. Adverse events related to the study drug were more frequent with 600 mg efavirenz than with 400 mg. Lower dose efavirenz should be recommended as part of routine care.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

*The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.*